Heddy Luise Holzhauser, MD
Advanced Heart Failure and Transplant Cardiology · Philadelphia, PANPI 1285973958
Payments from drug & device makers
What this record shows
This record is dominated by grants: $22,500 of the $26,332 with a category attached, or 85.4%. Medtronic accounts for 92.3% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $24,922 and has fallen 99.2% since, to $205 in 2025.
Across 63 payments — averaging $417.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$24K
- Abbott$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$171
- Vifor Pharma, Inc.$169
- One Lambda, Inc.$134
- Pfizer$131
- plus $375 from 6 others
What the payments were for
- Grants$22,50085%
- Travel & lodging$9013%
- Food & beverage$2,77911%
- Education$1511%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 17 | $24,310 |
| Abbott | 19 | $1,042 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $171 |
| Vifor Pharma, Inc. | 2 | $169 |
| One Lambda, Inc. | 2 | $134 |
| Pfizer | 7 | $131 |
| Bayer | 1 | $116 |
| Abiomed | 4 | $104 |
| Sanofi-aventis U.S. LLC | 1 | $86 |
| Amgen | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Merck | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,332 in reported general payments places this provider in the 70th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.
See all advanced heart failure and transplant cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 57 | $66,169 |
| JardianceEmpagliflozin | 21 | $27,102 |
| FarxigaDapagliflozin Propanediol | 12 | $12,850 |
| Tacrolimus | 16 | $4,271 |
| Atorvastatin Calcium | 54 | $640 |
| Metoprolol Succinate | 33 | $579 |
| Ezetimibe | 27 | $527 |
| Rosuvastatin Calcium | 19 | $475 |
| Famotidine | 16 | $391 |
| Potassium Chloride | 15 | $373 |
| Carvedilol | 50 | $276 |
| Spironolactone | 29 | $253 |
| Hydralazine Hcl | 16 | $247 |
| Amlodipine Besylate | 22 | $237 |
| Furosemide | 34 | $110 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Philadelphia
- Anjali VaidyaPhiladelphia$762K
- Jesus RamePhiladelphia$336K
- Ileana PinaPhiladelphia$284K
- Jeremy MazurekPhiladelphia$142K
- Lee GoldbergPhiladelphia$130K
- Anjali OwensPhiladelphia$109K
- Behnam BozorgniaPhiladelphia$107K
- Joyce WaldPhiladelphia$97K
- Paul MatherPhiladelphia$55K
- Hansie MathelierPhiladelphia$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.